{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:09:54Z","timestamp":1789070994911,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.7759\/cureus.116064","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:55:50Z","timestamp":1789070150000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study"],"prefix":"10.7759","author":[{"given":"Yamini","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala Venkat","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G V","family":"Deepthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranabandhu","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa Rao","family":"Bonala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021, 71:209-49. 10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mouri\u00f1o A","year":"2021","unstructured":"Casal-Mouri\u00f1o A, Ruano-Ravina A, Lorenzo-Gonz\u00e1lez M, et al.. Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021, 10:506-18. 10.21037\/tlcr.2020.03.40","journal-title":"Transl Lung Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2018.07.033","article-title":"Multimodality therapy for N2 non-small cell lung cancer: an evolving paradigm","volume":"107","author":"Spicer JD","year":"2019","unstructured":"Spicer JD, Shewale JB, Nelson DB, et al.. Multimodality therapy for N2 non-small cell lung cancer: an evolving paradigm. Ann Thorac Surg. 2019, 107:277-84. 10.1016\/j.athoracsur.2018.07.033","journal-title":"Ann Thorac Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2016.04.08","article-title":"Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer","volume":"5","author":"Rabatic BM","year":"2016","unstructured":"Rabatic BM, Kong FM. Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. Transl Lung Cancer Res. 2016, 5:190-4. 10.21037\/tlcr.2016.04.08","journal-title":"Transl Lung Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410","volume":"103","author":"Curran WJ Jr","year":"2011","unstructured":"Curran WJ Jr, Paulus R, Langer CJ, et al.. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011, 103:1452-60. 10.1093\/jnci\/djr325","journal-title":"J Natl Cancer Inst"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021455","article-title":"Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials","volume":"100","author":"Xiao W","year":"2021","unstructured":"Xiao W, Hong M. Concurrent vs sequential chemoradiotherapy for patients with advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021, 100:e21455. 10.1097\/MD.0000000000021455","journal-title":"Medicine (Baltimore)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2011.01.02","article-title":"Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine","volume":"3","author":"Provencio M","year":"2011","unstructured":"Provencio M, Isla D, S\u00e1nchez A, Cantos B. Inoperable stage III non-small cell lung cancer: current treatment and role of vinorelbine. J Thorac Dis. 2011, 3:197-204. 10.3978\/j.issn.2072-1439.2011.01.02","journal-title":"J Thorac Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002140.pub3","article-title":"Concurrent chemoradiotherapy in non-small cell lung cancer","volume":"2010","author":"O'Rourke N","year":"2010","unstructured":"O'Rourke N, Roqu\u00e9 I Figuls M, Farr\u00e9 Bernad\u00f3 N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010, 2010:CD002140. 10.1002\/14651858.CD002140.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-704","article-title":"Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review)","volume":"10","author":"\u0141azar-Poniatowska M","year":"2021","unstructured":"\u0141azar-Poniatowska M, Bandura A, Dziadziuszko R, Jassem J. Concurrent chemoradiotherapy for stage III non-small-cell lung cancer: recent progress and future perspectives (a narrative review). Transl Lung Cancer Res. 2021, 10:2018-31. 10.21037\/tlcr-20-704","journal-title":"Transl Lung Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1239-7","article-title":"Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Liu T","year":"2019","unstructured":"Liu T, He Z, Dang J, Li G. Comparative efficacy and safety for different chemotherapy regimens used concurrently with thoracic radiation for locally advanced non-small cell lung cancer: a systematic review and network meta-analysis. Radiat Oncol. 2019, 14:55. 10.1186\/s13014-019-1239-7","journal-title":"Radiat Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.03.055","article-title":"Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019","volume":"20","author":"Albain KS","year":"2002","unstructured":"Albain KS, Crowley JJ, Turrisi AT 3rd, et al.. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol. 2002, 20:3454-60. 10.1200\/JCO.2002.03.055","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.405","article-title":"Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol","volume":"23","author":"Belani CP","year":"2005","unstructured":"Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J, Curran WJ Jr. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol. 2005, 23:5883-91. 10.1200\/JCO.2005.55.405","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly ME","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, et al.. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022, 40:1356-84. 10.1200\/JCO.21.02528","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4280","article-title":"Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review","volume":"3","author":"Steuer CE","year":"2017","unstructured":"Steuer CE, Behera M, Ernani V, et al.. Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review. JAMA Oncol. 2017, 3:1120-9. 10.1001\/jamaoncol.2016.4280","journal-title":"JAMA Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1159\/000503095","article-title":"Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals","volume":"12","author":"Azam F","year":"2019","unstructured":"Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, Bukhari N. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019, 12:728-36. 10.1159\/000503095","journal-title":"Case Rep Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle U","year":"2018","unstructured":"Nestle U, De Ruysscher D, Ricardi U, et al.. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer. Radiother Oncol. 2018, 127:1-5. 10.1016\/j.radonc.2018.02.023","journal-title":"Radiother Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study","volume":"16","author":"Bradley JD","year":"2015","unstructured":"Bradley JD, Paulus R, Komaki R, et al.. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015, 16:187-99. 10.1016\/S1470-2045(14)71207-0","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)00060-C","article-title":"Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)","volume":"31","author":"Cox JD","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995, 31:1341-6. 10.1016\/0360-3016(95)00060-C","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz LH","year":"2016","unstructured":"Schwartz LH, Liti\u00e8re S, de Vries E, et al.. RECIST 1.1-update and clarification: from the RECIST committee. Eur J Cancer. 2016, 62:132-7. 10.1016\/j.ejca.2016.03.081","journal-title":"Eur J Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.02.011","article-title":"Randomized phase II study of concurrent cisplatin\/etoposide or paclitaxel\/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer","volume":"77","author":"Wang L","year":"2012","unstructured":"Wang L, Wu S, Ou G, et al.. Randomized phase II study of concurrent cisplatin\/etoposide or paclitaxel\/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2012, 77:89-96. 10.1016\/j.lungcan.2012.02.011","journal-title":"Lung Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.142","article-title":"Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin\/paclitaxel or cisplatin\/etoposide in stage III non-small cell lung cancer","volume":"2","author":"Liew MS","year":"2013","unstructured":"Liew MS, Sia J, Starmans MH, et al.. Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin\/paclitaxel or cisplatin\/etoposide in stage III non-small cell lung cancer. Cancer Med. 2013, 2:916-24. 10.1002\/cam4.142","journal-title":"Cancer Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx009","article-title":"Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial","volume":"28","author":"Liang J","year":"2017","unstructured":"Liang J, Bi N, Wu S, et al.. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. Ann Oncol. 2017, 28:777-83. 10.1093\/annonc\/mdx009","journal-title":"Ann Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2587","article-title":"Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data","volume":"33","author":"Santana-Davila R","year":"2015","unstructured":"Santana-Davila R, Devisetty K, Szabo A, et al.. Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. J Clin Oncol. 2015, 33:567-74. 10.1200\/JCO.2014.56.2587","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/527742-comparative-evaluation-of-concurrent-carboplatin-paclitaxel-versus-cisplatin-etoposide-chemoradiotherapy-in-unresectable-non-small-cell-lung-cancer-a-prospective-randomized-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:55:52Z","timestamp":1789070152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/527742-comparative-evaluation-of-concurrent-carboplatin-paclitaxel-versus-cisplatin-etoposide-chemoradiotherapy-in-unresectable-non-small-cell-lung-cancer-a-prospective-randomized-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.116064","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}